

November 14, 2018

Listing Department  
**BSE LIMITED**  
P J Towers, Dalal Street, Fort,  
Mumbai-400 001

Code: **532 321**

Listing Department  
**NATIONAL STOCK EXCHANGE OF INDIA LIMITED**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E),  
Mumbai-400 051

Code: **CADILAHC**

Re.: **Press Release**

Dear Sir / Madam,


Please find enclosed a copy of press release dated November 14, 2018 titled "Zydus receives final approval from the USFDA for Arsenic Trioxide Injection".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,  
For, **CADILA HEALTHCARE LIMITED**

  
**UPEN H. SHAH**  
**COMPANY SECRETARY**



Encl.: As above

## Zydus receives final approval from the USFDA for Arsenic Trioxide Injection

Ahmedabad, 14 November, 2018

Zydus Cadila has received the final approval from the USFDA to market Arsenic Trioxide Injection, 10 mg/10 mL (1 mg/mL) single-dose vial (US RLD – TRISENOX®). It will be manufactured at Alidac Pharmaceuticals Ltd., the company's wholly-owned subsidiary located at SEZ, Ahmedabad. Arsenic Trioxide is used to treat a type of leukemia (acute promyelocytic leukemia-APL) when other types of treatment (e.g., chemotherapy) have not worked well or no longer work.

The group now has 228 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

### About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

\*\*\*